MRNA Moderna Inc.
As of 3:42:00 PM ET
Loading chart…
- Open
- $258.01
- Previous close
- $258.38
- Day range
- 237.69 – 260.62
- 52-week range
- 22.28 – 260.62
- Volume
- 377.1K
- Avg volume (3M)
- 22M
- Market cap
- $88.2B
- P/E (TTM)
- 24.97
- EPS (TTM)
- −$7.98
- Beta
- 1.10
- Dividend yield
- 0.00%
- Next earnings
- —
- Ex-dividend
- —
- Sector
- Healthcare
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing medicines and vaccines based on messenger RNA (mRNA) technology. Its commercial portfolio includes respiratory and infectious disease vaccines, while its broader pipeline spans oncology, rare diseases, autoimmune conditions, and other therapeutic areas. Moderna uses its mRNA platform to design products that instruct cells to produce proteins or immune responses relevant to prevention and treatment. The company also works with manufacturing and commercialization capabilities to support product development and distribution across major healthcare markets. Headquartered in Cambridge, Massachusetts, Moderna plays a significant role in the biopharmaceutical industry by advancing a new class of medicines across vaccines and therapeutics.
| Quarter | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Jul 31, 2026(after close) | −$2.06 | −$1.97 | −4.4% |
| May 22, 2026(after close) | $1.34 | $1.78 | +32.8% |
| May 1, 2026(after close) | −$3.88 | −$3.40 | −12.4% |
| Mar 17, 2026(after close) | $0.42 | $0.65 | +54.8% |
| Mar 4, 2026(after close) | $0.06 | $0.15 | +150.0% |
MRNA doesn’t pay a dividend.
MRNA news and filings
Loading filings…
Filings from SEC EDGAR.